Compare Stocks → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:KTOVNASDAQ:SAVANASDAQ:SEELNASDAQ:VBLTNASDAQ:ZSAN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKTOVPurple Biotech$0.52$4.16$2.20▼$14.40$8.11M2.371.18 million shs1.69 million shsSAVACassava Sciences$22.36+2.9%$21.44$12.32▼$32.10$967.07M-0.45763,848 shs645,633 shsSEELSeelos Therapeutics$0.29+1.8%$0.72$0.28▼$49.80$3.98M1.88430,357 shs514,319 shsVBLTVascular Biogenics$5.46-8.8%$0.40$0.10▼$6.74$423.91M0.772.19 million shs161,505 shsZSANZosano Pharma$0.00$3.90$0.46▼$37.45$1K3.3425,375 shs5,685 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKTOVPurple Biotech0.00%+11.21%-17.55%-22.59%-74.11%SAVACassava Sciences+4.77%+2.55%+10.25%-10.32%+40.91%SEELSeelos Therapeutics-5.12%-15.50%-45.86%-73.31%-98.56%VBLTVascular Biogenics0.00%0.00%0.00%0.00%+3,169.46%ZSANZosano Pharma0.00%0.00%0.00%0.00%0.00%Move Your Money Before May 1 (Ad)Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKTOVPurple BiotechN/AN/AN/AN/AN/AN/AN/AN/ASAVACassava Sciences3.2506 of 5 stars3.50.00.04.72.30.00.6SEELSeelos Therapeutics1.9494 of 5 stars3.24.00.00.00.60.00.0VBLTVascular BiogenicsN/AN/AN/AN/AN/AN/AN/AN/AZSANZosano PharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKTOVPurple BiotechN/AN/AN/AN/ASAVACassava Sciences3.00Buy$124.00454.56% UpsideSEELSeelos Therapeutics2.33Hold$70.0023,971.53% UpsideVBLTVascular BiogenicsN/AN/AN/AN/AZSANZosano PharmaN/AN/AN/AN/ACurrent Analyst RatingsLatest SAVA, VBLT, KTOV, ZSAN, and SEEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/5/2024SAVACassava SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$124.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKTOVPurple Biotech$1M8.11N/AN/A$5.56 per share0.09SAVACassava SciencesN/AN/AN/AN/A$3.26 per shareN/ASEELSeelos Therapeutics$2.20M1.81N/AN/A($3.42) per share-0.09VBLTVascular Biogenics$660K642.29N/AN/A$0.32 per share17.06ZSANZosano Pharma$790K0.00N/AN/A$9.74 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKTOVPurple Biotech-$5.85M-$3.00N/AN/AN/AN/AN/AN/AN/ASAVACassava Sciences-$97.22M-$2.32N/A13.39N/AN/A-57.53%-52.58%5/6/2024 (Estimated)SEELSeelos Therapeutics-$37.88MN/A0.00∞N/A-1,719.56%N/A-517.23%5/20/2024 (Estimated)VBLTVascular Biogenics-$32.30M-$0.21N/A∞N/AN/A-73.45%-54.11%N/AZSANZosano Pharma-$29.92M-$14.50N/A∞N/A-8,375.11%-177.06%-119.14%N/ALatest SAVA, VBLT, KTOV, ZSAN, and SEEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/28/2024Q4 2023SAVACassava Sciences-$0.40-$0.50-$0.10-$0.50N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKTOVPurple BiotechN/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/ASEELSeelos TherapeuticsN/AN/AN/AN/AN/AVBLTVascular BiogenicsN/AN/AN/AN/AN/AZSANZosano PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKTOVPurple BiotechN/A2.22N/ASAVACassava SciencesN/A9.139.13SEELSeelos TherapeuticsN/A0.140.14VBLTVascular BiogenicsN/A4.634.63ZSANZosano PharmaN/A1.611.61OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKTOVPurple Biotech30.72%SAVACassava Sciences38.05%SEELSeelos Therapeutics23.37%VBLTVascular Biogenics0.96%ZSANZosano PharmaN/AInsider OwnershipCompanyInsider OwnershipKTOVPurple Biotech2.98%SAVACassava Sciences9.00%SEELSeelos Therapeutics5.40%VBLTVascular Biogenics6.13%ZSANZosano Pharma2.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableKTOVPurple Biotech915.73 millionN/ANot OptionableSAVACassava Sciences2943.25 million39.35 millionOptionableSEELSeelos Therapeutics1513.68 million12.94 millionOptionableVBLTVascular Biogenics777.64 million72.88 millionOptionableZSANZosano Pharma404.90 million4.78 millionNot OptionableSAVA, VBLT, KTOV, ZSAN, and SEEL HeadlinesSourceHeadlineHOOK HOOKIPA Pharma Inc.seekingalpha.com - April 12 at 10:11 PMNachrichten - Weitere Nachrichtenwallstreet-online.de - January 9 at 2:39 PMLISTEN: Supreme Court hears arguments on legality of Purdue Pharma bankruptcy planpbs.org - December 6 at 7:44 AMDer Börsen-Tag: Diese US-Aktie stürzte nachbörslich abn-tv.de - August 22 at 3:36 PMEast Bay Business Newsbizjournals.com - May 18 at 9:49 PMMankind Pharma IPO opens on April 25, listing scheduled for May 9moneycontrol.com - April 27 at 4:20 PMAstellas Pharmaforbes.com - April 6 at 12:00 PMGiiant Pharma Receives Financial Support From the US Crohn’s and Colitis Foundationfinance.yahoo.com - February 5 at 12:11 PMFTC asks court to hold 'pharma bro' Martin Shkreli in contempt for failing to abide by orderswashingtonexaminer.com - January 23 at 3:25 PMZosano Pharma Corporation (ZSANQ)ca.finance.yahoo.com - November 5 at 6:33 PMNow bankrupt, Zosano sells off its drug delivery tech that once enticed Novo Nordisk, Eli Lillyendpts.com - October 13 at 11:22 AMBankrupt Zosano Sells Its Drug Delivery Tech That Once Partnered With Pharma Giantsmsn.com - October 12 at 2:32 PMBankrupt Zosano Pharma Says Unsecured Creditors Will Recoup 28% of Claimsmarketwatch.com - August 28 at 7:45 PMEast Bay migraine patch developer Zosano closes sale in bankruptcy court for $1 millionbizjournals.com - August 27 at 4:10 PMZosano Pharma Corp (ZSANQ)investing.com - August 25 at 12:28 AMEast Bay company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1Mbizjournals.com - July 26 at 8:27 PMA Fremont company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1M.bizjournals.com - July 26 at 8:27 PMZosano Pharma Corporation [ZSAN] stock Initiated by Maxim Group analyst, price target now $8dbtnews.com - June 3 at 11:27 AMZosano Pharma Shares Slide to New Depths After Chapter 11 Filing >ZSANmarketwatch.com - June 2 at 3:26 PMWhy Zosano Pharma Shares Are Getting Hammered Todaymsn.com - June 2 at 3:26 PMZosano Pharma files for Chapter 11 bankruptcy protection; shares plummet 46%seekingalpha.com - June 2 at 10:26 AMCash-Strapped Zosano Pharma Files for Chapter 11 Bankruptcy >ZSANmarketwatch.com - June 2 at 10:26 AMEast Bay migraine patch developer files for bankruptcybizjournals.com - June 2 at 10:26 AMZosano Pharma Files Voluntary Petition for Relief Under Chapter 11finance.yahoo.com - June 2 at 10:26 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsPurple BiotechNASDAQ:KTOVPurple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. is headquartered in Tel Aviv, Israel.Cassava SciencesNASDAQ:SAVACassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.Seelos TherapeuticsNASDAQ:SEELSeelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.Vascular BiogenicsNASDAQ:VBLTVascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.Zosano PharmaNASDAQ:ZSANZosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.